

CITATION REPORT

List of articles citing

Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era

DOI: 10.1164/rccm.200806-953oc

American Journal of Respiratory and Critical Care Medicine, 2009, 179, 151-7.

Source: <https://exaly.com/paper-pdf/45704145/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
536	Pulmonary vascular pathology. 661-710		2
535	Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension. 2009 , 1, CMT.S2675		
534	Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother?. <i>Rheumatology</i> , 2009 , 48, 1471-2	3.9	3
533	Identification of Fibrocytes in Peripheral Blood. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 1279-1280	10.2	
532	Survival in systemic sclerosis-related pulmonary arterial hypertension in the modern treatment era. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 1280; author reply 1280-1	10.2	2
531	Update in pulmonary hypertension 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 650-6	10.2	24
530	Recent Advances in the Management of Pulmonary Arterial Hypertension. 2009 , 5, 41-48		
529	Opportunities and challenges in the study of pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 91-2	10.2	7
528	Pulmonary arterial hypertension complicating connective tissue diseases. 2009 , 30, 429-39		48
527	Cardiovascular disease complications in systemic lupus erythematosus. 2009 , 3, 239-52		12
526	Screening for pulmonary arterial hypertension in systemic sclerosis. 2009 , 18, 162-9		38
525	Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2009 , 48, 1137-42	3.9	64
524	[Key features in the management of diffuse interstitial pulmonary disease]. 2009 , 45 Suppl 3, 3-8		1
523	Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. 2010 , 40, 494-502		6
522	[Pulmonary arterial hypertension in collagenoses]. 2009 , 68, 630-2, 634-8		2
521	Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. 2009 , 103, 1713-8		28
520	Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. 2009 , 10, 32		23

519	Survival in Systemic Sclerosis-Related Pulmonary Arterial Hypertension in the Modern Treatment Era. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 1280-1281	10.2
518	Current world literature. 2009 , 21, 656-65	
517	Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. 2010 , 138, 1383-94	289
516	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. 2010 , 16 Suppl 1, S27-34	16
515	Current world literature. 2010 , 22, 704-12	
514	Pulmonary arterial hypertension in connective tissue diseases. 2010 , 18, 85-8	12
513	Cardiac complications of systemic sclerosis: recent progress in diagnosis. 2010 , 22, 696-703	26
512	In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans. 2010 , 5, 409-16	1
511	[Scleroderma]. 2010 , 51, 30-8	5
510	Pulmonale Hypertonie. 2010 , 7, 165-173	
509	Secondary pulmonary hypertension. 2010 , 3, 1-9	3
508	Pulmonary arterial hypertension in systemic sclerosis. 2010 , 9, 761-70	21
507	Evidence-based management of rapidly progressing systemic sclerosis. 2010 , 24, 387-400	52
506	Epidemiology of systemic sclerosis. 2010 , 24, 857-69	76
505	Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. 2010 , 62, 3741-50	57
504	Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease. 2010 , 17, 282-6	14
503	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. <i>Rheumatology</i> , 2010 , 49, 490-500	3.9 74
502	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , 2010 , 49, 940-4	3.9 44

501	Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. 2010 , 5, 555-564		1
500	Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. 2010 , 121, 2045-66		367
499	Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. 2010 , 19, 314-20		21
498	Management of severe pulmonary arterial hypertension. 2010 , 19, 279-87		13
497	Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. 2010 , 37, 2290-8		198
496	Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. 2010 , 2010, 720305		58
495	Role of inflammation in pulmonary arterial hypertension. 2010 , 2, 2		1
494	Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2010 , 49, 2147-53	3.9	11
493	Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. 2010 , 35, 95-104		100
492	Genetic background of systemic sclerosis: autoimmune genes take centre stage. <i>Rheumatology</i> , 2010 , 49, 203-10	3.9	35
491	Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. 2010 , 2010,		47
490	Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. 2010 , 37, 987-92		50
489	Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. 2010 , 138, 461-2; author reply 462-3		2
488	Pulmonary arterial hypertension and lung transplantation. 2010 , 31, 147-60		12
487	Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 252-60	10.2	173
486	[Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S67-77		7
485	Systemic sclerosis-associated pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 1285-93	10.2	74
484	Update on pulmonary hypertension 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 1020-6	10.2	12

483	Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. 2010 , 29, 188-94		21
482	Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. 2010 , 103, 46-52		89
481	Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. 2010 , 103, 109-15		105
480	Emerging drugs for pulmonary hypertension. 2010 , 15, 71-85		11
479	Maladies vasculaires pulmonaires. 2011 , 3, 128-139		
478	Hypertension artérielle pulmonaire associée aux connectivites : particularités cliniques et pronostiques. 2011 , 3, S49-S55		
477	Interstitial lung disease: the initial approach. 2011 , 95, 1071-93		7
476	Assessment of pulmonary hypertension during exercise: ready for clinical prime time?. 2011 , 104, 211-5		1
475	Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. 2011 , 8, 53-82		112
474	Platelet-derived growth factor receptor- α and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. <i>Arthritis Research and Therapy</i> , 2011, 13, R61	5-7	33
473	Long-term effects of intermittent iloprost infusion on pulmonary arterial pressure in connective tissue disease. 2011 , 22, 518-21		18
472	Lung involvement in systemic sclerosis. 2011 , 40, e3-e17		21
471	[Connective tissue disease and the lung]. 2011 , 32 Suppl 2, S241-4		
470	[Pulmonary hypertension in interstitial lung diseases: diagnostic and therapeutic approach in 2011?]. 2011 , 40 Suppl 1, 1S39-45		0
469	[Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls]. 2011 , 40 Suppl 1, 1S46-53		0
468	Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S3-12		57
467	Pulmonary hypertension: screening and evaluation in scleroderma. 2011 , 23, 536-44		14
466	Survival in pulmonary hypertension registries: the importance of incident cases. 2011 , 139, 1547-1548		1

465	Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. 2011 , 139, 1285-1293		100
464	Survival in Pulmonary Hypertension Registries: Response. 2011 , 139, 1548-1549		2
463	Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?. 2011 , 65, 1-3		4
462	Pulmonary hypertension in systemic sclerosis. 2011 , 41, 19-37		31
461	Scleroderma lung disease. 2011 , 40, 104-16		30
460	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. 2011 , 63, 2456-64		87
459	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. 2011 , 63, 2790-6		40
458	Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPGSS). 2011 , 38, 2419-27		2
457	Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. 2011 , 20, 277-86		68
456	The Wisdom of the PHAROS. 2011 , 38, 2089-91		1
455	CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2011 , 50, 1480-6	3.9	27
454	Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. 2011 , 20, 270-6		20
453	Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success?. 2011 , 20, 218-9		2
452	Living with pulmonary hypertension: quality not just quantity. 2011 , 38, 512-3		3
451	Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. 2011 , 140, 301-309		127
450	Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. 2011 , 139, 994-1002		45
449	Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. 2011 , 38, 2410-8		87
448	Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. 2011 , 140, 1016-1024		73

447	Pulmonary arterial hypertension associated with systemic sclerosis. 2011 , 5, 267-79		28
446	Hemodynamic monitoring in pulmonary arterial hypertension. 2011 , 5, 173-8		5
445	Implications of exercise-induced pulmonary arterial hypertension. 2011 , 43, 983-9		20
444	Optimal management of severe pulmonary arterial hypertension. 2011 , 20, 254-61		15
443	Pulmonary hypertension secondary to interstitial lung disease. 2011 , 5, 179-89		16
442	Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. 2012 , 39, 1265-74		58
441	Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. <i>Rheumatology</i> , 2012 , 51, 1846-54	3.9	46
440	Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. 2012 , 2012, 854941		50
439	Abstracts of the 34th Scandinavian Congress of Rheumatology. Copenhagen, Denmark. September 2-5, 2012. 2012 , 126, 1-68		
438	Pulmonary arterial hypertension: bridging the present to the future. 2012 , 21, 267-70		8
437	Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. 2012 , 263, 678-87		63
436	Early detection and management of pulmonary arterial hypertension. 2012 , 21, 306-12		67
435	ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. 2012 , 39, 945-55		260
434	Pulmonary vascular responses to exercise: a haemodynamic observation. 2012 , 39, 231-4		24
433	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. 2012 , 71, 1335-42		67
432	Aging and Lung Disease. 2012 ,		
431	Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. 2012 , 21, 353-64		28
430	Challenges in the diagnosis and treatment of pulmonary arterial hypertension. 2012 , 21, 313-20		35

429	Pulmonary hypertension in parenchymal lung disease. 2012 , 2012, 684781	4
428	Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. 2012 , 98, 1805-11	177
427	Survival and extrapulmonary course of connective tissue disease after lung transplantation. 2012 , 18, 283-9	23
426	Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. 2012 , 64, 4072-7	45
425	Classification of pulmonary hypertension. 2012 , 8, 301-17	10
424	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. 2012 , 71, 1382-7	80
423	The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. 2012 , 71, 249-52	52
422	Hemodynamics in pulmonary arterial hypertension: current and future perspectives. 2012 , 110, 9S-15S	33
421	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. 2012 , 64, 2995-3005	82
420	Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R213	5-7 66
419	Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. 2012 , 42, 1351-4	13
418	Pulmonary arterial hypertension in connective tissue diseases. 2012 , 8, 413-25	47
417	Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. 2012 , 15, e80-9	18
416	Complex Challenges of Pulmonary Hypertension. 2012 , 447-460	1
415	Clinical Assessment of Pulmonary Hypertension. 2012 , 429-435	
414	The imaging of pulmonary hypertension. 2012 , 33, 535-51	24
413	Predicting survival in pulmonary arterial hypertension in the UK. 2012 , 40, 604-11	84
412	Connective tissue disease-associated lung disease. 2012 , 32, 513-36	29

411	Diagnostic dilemmas in pulmonary hypertension. 2012 , 8, 331-52		1
410	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R143	5-7	65
409	Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. <i>Arthritis Research and Therapy</i> , 2012 , 14, R148	5-7	79
408	Pulmonary Hypertension. 2012 , 355-366		
407	Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders. 2012 , 94-104		
406	Exercise Testing in Pulmonary Arterial Hypertension. 2012 , 37-47		2
405	Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. 2012 , 64, 1257-62		47
404	Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. 2012 , 12, 180-3		11
403	Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. 2012 , 32, 1727-31		43
402	Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. 2012 , 64, 303-10		27
401	An update on the evaluation and management of pulmonary hypertension in scleroderma. 2012 , 14, 1-10		5
400	Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. <i>Clinical Rheumatology</i> , 2013 , 32, 1519-31	3-9	45
399	Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. 2013 , 33, 1655-67		40
398	Lung transplantation and atrial septostomy in pulmonary arterial hypertension. 2013 , 34, 857-65		6
397	Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. 2013 , 65, 2412-23		153
396	Connective tissue diseases: To screen or not to screen for PAH in connective tissue diseases?. 2013 , 9, 699-700		
395	Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. 2013 , 29, 659-61		3
394	Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. 2013 , 12, 410-5		54

393	Pharmacotherapy of Pulmonary Hypertension. 2013,		2
392	Pulmonary arterial hypertension in SLE: what do we know?. 2013, 22, 1274-85		21
391	Pulmonary hypertension in systemic lupus erythematosus. 2013, 27, 425-34		12
390	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. 2013, 65, 3194-201		131
389	Pulmonary hypertension in chronic lung diseases. 2013, 62, D109-16		390
388	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy, 2013, 15,</i> R193	5.7	37
387	Epidemiology of pulmonary arterial hypertension. 2013, 15, 638-49		15
386	Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. 2013, 65, 1074-84		107
385	Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. <i>Rheumatology, 2013, 52,</i> 155-60	3.9	122
384	Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. 2013, 7, 227-36		20
383	Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. <i>Rheumatology, 2013, 52,</i> 1208-13	3.9	50
382	The Fra-2 transgenic mouse model of systemic sclerosis. 2013, 58, 194-201		44
381	Treatment goals of pulmonary hypertension. 2013, 62, D73-81		207
380	Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. 2013, 111, 1A-16A; quiz 17A-19A		48
379	Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review. 2013, 43, 751-60		9
378	Perioperative Management of Patients with Rheumatic Disease. 2013,		2
377	Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. 2013, 3,		14
376	[Early diagnosis and therapy in pulmonary hypertension--aspects of a vision]. 2013, 67, 376-87		0

375	Pulmonary hypertension complicating connective tissue disease. 2013 , 34, 581-99	4
374	Stress echocardiography and Cochin Risk Prediction Score for the prediction of pulmonary arterial hypertension in scleroderma: not yet ready for prime time. 2013 , 65, 2236-9	2
373	Updating clinical endpoint definitions. 2013 , 3, 206-16	19
372	From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. 2013 , 3, 507-22	5
371	Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. 2013 , 128, 1470-9	244
370	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. 2013 , 22, 515-25	20
369	Perioperative Management of the Patient with Pulmonary Hypertension. 2013 , 137-154	1
368	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. 2013 , 72, 1940-6	89
367	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. 2013 , 23, 1211-1220	16
366	Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. 2013 , 144, 1282-1290	55
365	Outcomes in systemic sclerosis-related lung disease after lung transplantation. 2013 , 95, 975-80	58
364	Cardiopulmonary Disease in SLE. 2013 , 352-362	
363	Pulmonary hypertension secondary to hyperviscosity in a patient with rheumatoid arthritis and acquired von Willebrand disease: a case report. 2013 , 7, 232	2
362	The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension. 2014 , 2, 120-147	4
361	Cardiac manifestations in systemic sclerosis. 2014 , 6, 993-1005	84
360	Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. 2014 , 44, 963-72	72
359	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 493	5-7 36
358	Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort. 2014 , 43, 314-23	11

357	Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. <i>Rheumatology</i> , 2014 , 53, 285-92	3.9	37
356	Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers. 2014 , 4, 679-84		6
355	Pulmonary Manifestations of Systemic Lupus Erythematosus (SLE). 2014 , 61-72		2
354	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. 2014 , 146, 1494-1504		94
353	Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. 2014 , 93, 177-185		21
352	[Modern imaging methods in the management of pulmonary hypertension]. 2014 , 139 Suppl 4, S121-5		1
351	Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis. 2014 , 171, 3463-75		9
350	Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. 2014 , 66, 489-95		100
349	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. 2014 , 130, 2189-208		209
348	Connective tissue disease-associated pulmonary arterial hypertension: "Beijing style". 2014 , 44, 839-41		2
347	Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. 2014 , 23, 1085-91		54
346	Experience with exercise right heart catheterization in the diagnosis of pulmonary hypertension: a retrospective study. 2014 , 9, 51		14
345	Recent advances in scleroderma-associated pulmonary hypertension. 2014 , 26, 637-45		10
344	Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. 2014 , 26, 131-7		41
343	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases. 2014 , 9, S26-37		3
342	Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014 , 11 Suppl 3, S178-85	4.7	29
341	Assessment of Kinesiophobia and Use of Music Therapy in the Acute Care Setting. 2014 , 5, 89-97		
340	Improved survival in limited scleroderma-related pulmonary artery hypertension. 2014 , 9, 385-96		2

339	Pulmonary manifestations of systemic lupus erythematosus. 2014 , 35, 249-54		49
338	Pulmonary Manifestations of Rheumatic Disease. 2014 ,		2
337	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. 2014 , 43, 536-41		15
336	Pulmonary arterial hypertension related to connective tissue disease: a review. 2014 , 40, 103-24		26
335	Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. 2014 , 66, 1900-8		34
334	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. 2014 , 20, 1289-300		183
333	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. 2014 , 73, 1340-9		444
332	[Pulmonary arterial hypertension associated with connective tissue diseases]. 2014 , 43, 957-69		3
331	Update in systemic sclerosis-associated pulmonary arterial hypertension. 2014 , 43, e293-304		20
330	Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 190, 808-17	10.2	129
329	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. 2014 , 73, 191-7		35
328	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. 2014 , 43, e345-63		34
327	Mortality from nonneoplastic skin disease in the United States. 2014 , 70, 47-54.e1		5
326	Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin. 2014 , 118, 313-28		15
325	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 2014 , 13, 295-305		15
324	Successful use of intensive immunosuppressive therapy for treating simultaneously occurring cerebral lesions and pulmonary arterial hypertension in a patient with systemic lupus erythematosus. <i>Internal Medicine</i> , 2014 , 53, 627-31	1.1	9
323	Characterization of patients with borderline pulmonary arterial pressure. 2014 , 146, 1486-1493		51
322	The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. 2014 , 145, 1230-1236		117

321	Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. 2014 , 146, 959-966		28
320	At high cardiac output, diesel exhaust exposure increases pulmonary vascular resistance and decreases distensibility of pulmonary resistive vessels. 2015 , 309, H2137-44		22
319	Changes in Right Ventricular Function with Exercise in Healthy Subjects: Optimal Parameters and Effects of Gender and Age. 2015 , 28, 1441-51.e1		9
318	Ankylosing spondylitis associated with pulmonary arterial hypertension. <i>Internal Medicine</i> , 2015 , 54, 431-41		2
317	Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. 2015 , 9, 97-110		11
316	Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. 2015 , 67, 2457-65		9
315	Connective tissue disease-associated pulmonary arterial hypertension. 2015 , 7, 06		32
314	Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition. 2015 , 2015, 328435		8
313	The right ventricle in scleroderma (2013 Grover Conference Series). 2015 , 5, 3-14		16
312	Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2015 , 41, 489-506		8
311	Diagnosis and Management of Pulmonary Hypertension. 2015 ,		
310	Pulmonary vascular response patterns during exercise in interstitial lung disease. 2015 , 46, 738-49		34
309	Reply: vascular receptor autoantibodies in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 602-3	10.2	1
308	Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2015 , 17, 165	5-7	35
307	An evidence-based approach to screening and diagnosis of pulmonary hypertension. 2015 , 31, 382-90		10
306	Connective tissue disease-associated pulmonary arterial hypertension. 2015 , 41, 295-313		13
305	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5-7	63
304	Exercise Echocardiography in Connective Tissue Disease. 2015 , 66, 385-7		3

303	Idiopathic inflammatory myopathies and the lung. 2015 , 24, 216-38		80
302	Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy. 2015 , 42, 50-4		1
301	Continuing Progress in Vasculitis Research. Abstracts of the 17th International Vasculitis & ANCA Workshop London, April 19-22, 2015: Abstracts. 2015 , 129 Suppl 2, 1-44		7
300	[Antisynthetase syndrome with pulmonary hypertension: 4 original observations]. 2015 , 36, 794-9		3
299	Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition?. <i>Arthritis Research and Therapy</i> , 2015 , 17, 123	5-7	7
298	Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. <i>Rheumatology</i> , 2015 , 54, 1673-9	3-9	33
297	Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressure. 2015 , 25, 744-7		2
296	Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. 2015 , 20, 481-7		11
295	Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome. 2015 , 10, 149-160		1
294	Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1111-7	10.2	46
293	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1102-10	10.2	97
292	Exercise-induced pulmonary hypertension: at last!. 2015 , 46, 583-6		28
291	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. 2015 , 3, 1-8		42
290	Early detection of pulmonary arterial hypertension. 2015 , 12, 143-55		84
289	[Pulmonary manifestations of antisynthetase syndrome]. 2015 , 32, 618-28		5
288	Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension. 2015 , 74, 67-71		5
287	Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?. 2016 , 2,		2
286	Elevated galectin-3 level predicts pulmonary artery hypertension. 2016 , 3, 89-97		1

285	The Lung in Systemic Lupus Erythematosus. 2016 , 383-389	
284	SAPHIRE: Stress and Pulmonary Hypertension in Rheumatoid Evaluation-A Prevalence Study. 2016 , 2016, 4564531	1
283	Belastungstests bei pulmonal-arterieller Hypertonie. 2016 , 4, 64-76	
282	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. 2016 , 95, e2761	43
281	Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. 2016 , 68, 484-93	48
280	Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. <i>Arthritis Research and Therapy</i> , 2016 , 18, 153	5-7 8
279	Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension. 2016 , 65, 215-22	6
278	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. 2016 , 48, 1658-1667	35
277	To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. 2016 , 48, 1549-1552	3
276	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. 2016 , 6, e011028	9
275	Risk assessment in pulmonary arterial hypertension. 2016 , 25, 390-398	25
274	Physiological Techniques and Pulmonary Hypertension - Left Heart Disease. 2016 , 59, 30-41	1
273	Pulmonary haemodynamics during recovery from maximum incremental cycling exercise. 2016 , 48, 158-67	21
272	Mixed connective tissue disease. 2016 , 30, 95-111	60
271	Pulmonary arterial hypertension and associated conditions. 2016 , 62, 379-402	5
270	Exercise pulmonary haemodynamics: a test in search of purpose. 2016 , 47, 1315-7	1
269	Hypertension artérielle pulmonaire associée aux connectivites. 2016 , 37, A22-A26	
268	Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up. 2016 , 19, 27-30	10

267	Contemporary diagnosis and management of pulmonary hypertension. 2016 , 102, 1680-91		3
266	[Clinical classification and initial diagnosis of pulmonary hypertension: recommendations of the Cologne Consensus Conference 2016]. 2016 , 141, S10-S18		4
265	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. 2016 , 117, 254-63		17
264	Does exercise pulmonary hypertension exist?. 2016 , 22, 400-7		4
263	Connective tissue disease-related pulmonary arterial hypertension. 2016 , 30, 22-38		26
262	Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 30	5-7	21
261	Belastungsuntersuchungen in der Pneumologie. 2016 , 13, 209-219		
260	Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. 2016 , 11, 941-52		3
259	Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic-pathophysiologic classification. 2016 , 35, 610-8		16
258	Proposed new definition of exercise pulmonary hypertension decreases false-positive cases. 2016 , 47, 1270-3		18
257	Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors. 2016 , 43, 323-9		14
256	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. 2016 , 15, 250-7		29
255	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. 2016 , 47, 1436-44		31
254	Monitoring of Lung Involvement in Rheumatologic Disease. 2016 , 91, 89-98		12
253	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). 2016 , 18, 10		28
252	Management of interstitial lung disease associated with connective tissue disease. 2016 , 352, h6819		137
251	Connective tissue diseases, multimorbidity and the ageing lung. 2016 , 47, 1535-58		20
250	Exercise testing can unmask right ventricular dysfunction in systemic sclerosis patients with normal resting pulmonary artery pressure. 2016 , 204, 179-86		15

249	Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. 2016 , 47, 1179-88		59
248	Pulmonary vascular and cardiac impairment in interstitial lung disease. 2017 , 26,		24
247	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. 2017 , 236, 432-437		48
246	Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes. 2017 , 152, 92-102		28
245	Transforming growth factor- β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma. 2017 , 312, L22-L31		20
244	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. 2017 , 36, 770-779		47
243	Pulmonary hypertension in connective tissue diseases: an update. 2017 , 20, 5-24		26
242	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017 , 19, 42	5-7	37
241	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. 2017 , 49,		25
240	Distinctive metabolomic fingerprint in scleroderma patients with pulmonary arterial hypertension. 2017 , 241, 401-406		18
239	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. 2017 , 7, 654-665		30
238	Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension. 2017 , 34, 817-824		
237	Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus. 2017 , 5, 2050313X17707153		
236	Open label study of ambrisentan in patients with exercise pulmonary hypertension. 2017 , 7, 531-538		14
235	Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension. 2017 , 7, 572-587		13
234	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. 2017 , 52, 1495-1503		62
233	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. 2017 , 208, 1229-1236		37
232	Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 682-689	4-7	10

231	Readdressing the entity of exercise pulmonary arterial hypertension. 2017 , 124, 65-71		2
230	Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. <i>Clinical Rheumatology</i> , 2017 , 36, 381-390	3-9	21
229	Cardiopulmonary Manifestations of Collagen Vascular Diseases. 2017 , 19, 71		9
228	Understanding exercise hemodynamics. 2017 , 7, 565-566		
227	Screening of Pulmonary Arterial Hypertension. 2017 , 38, 596-605		1
226	Pulmonary Hypertension Complicating Connective Tissue Disease. 2017 , 38, 619-635		4
225	Pulmonary Hypertension: Definition, Classification, and Diagnosis. 2017 , 38, 561-570		5
224	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , 2017 , 56, v33-v37	3-9	4
223	New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. 2017 , 29, 561-567		3
222	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. 2017 , 50,		58
221	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. 2017 , 50,		20
220	Unmasking hidden disease: exercise pulmonary haemodynamics in systemic sclerosis. 2017 , 50,		3
219	Diagnosing and managing scleroderma-related pulmonary arterial hypertension. 2017 , 30, 11-18		1
218	Trends in comorbidity in patients hospitalised for cardiovascular disease. 2017 , 248, 382-388		19
217	Screening auf pulmonale Hypertonie. 2017 , 14, 153-159		
216	Overview of Lung Involvement: Diagnosis, Differential Diagnosis and Monitoring. 2017 , 359-362		
215	The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis. 2017 , 411-419		
214	Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. 2017 , 27, 481-488		4

- 213 Search for an animal model to investigate selective pulmonary vasodilation. **2017**, 51, 376-387
- 212 Exercise-induced pulmonary hypertension by stress echocardiography: Prevalence and correlation with right heart hemodynamics. **2017**, 228, 518-522 5
- 211 Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. **2017**, 20, 1227-1236 15
- 210 An official European Respiratory Society statement: pulmonary haemodynamics during exercise. **2017**, 50, 124
- 209 Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. *Journal of Scleroderma and Related Disorders*, **2017**, 2, 92-99 2-3 5
- 208 Pulmonary arterial hypertension screening of systemic sclerosis patients in clinical practice: an independent chart review. *Journal of Scleroderma and Related Disorders*, **2017**, 2, 231-234 2-3 1
- 207 Pulmonary Hypertension in Systemic Sclerosis. **2017**,
- 206 An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. **2018**, 20, 10 15
- 205 Diagnostic criteria, severity classification and guidelines of systemic sclerosis. **2018**, 45, 633-691 16
- 204 [Pulmonary hypertension in connective tissue disease]. **2018**, 77, 219-230
- 203 Exercise-Induced Pulmonary Hypertension: Translating Pathophysiological Concepts Into Clinical Practice. **2018**, 154, 10-15 47
- 202 The prognosis of pulmonary arterial hypertension associated with primary Sjögren's syndrome: a cohort study. **2018**, 27, 1072-1080 18
- 201 Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study. **2018**, 196, 165-171 2
- 200 Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. **2018**, 48, e12876 17
- 199 Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. **2018**, 12, 145-160 7
- 198 Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. **2018**, 82, 546-554 23
- 197 Pulmonary arterial hypertension associated to systemic erythematosus lupus: molecular characterization of 3 cases. **2018**, 151, 111-115
- 196 Pulmonary hypertension in patients with interstitial lung disease. **2018**, 50, 38-46 13

195	Stressing the Cardiopulmonary Vascular System: The Role of Echocardiography. 2018 , 31, 527-550.e11	26
194	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. 2018 , 77, 128-132	17
193	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. 2018 , 137, 693-704	92
192	Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. 2018 , 8, 2045893217735820	49
191	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. 2018 , 153, 143-151	35
190	Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis. 2018 , 33, 191-197	2
189	Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. 2018 , 153, 310-320	12
188	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. 2018 , 134, 42-46	15
187	Exercise testing in heart failure: a contemporary discussion in an era of novel diagnostic techniques and biomarkers. 2018 , 33, 217-224	1
186	Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. 2019 , 35, 86-89	4
185	Long-term survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Insights from a referral center in Portugal. 2018 , 37, 749-757	2
184	Lung Transplantation in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). 2018 , 7, 160-168	2
183	Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension. 2018 , 52,	4
182	Pulmonale Hypertonie und rheumatische Erkrankungen. 2018 , 15, 396-403	
181	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. 2018 , 52,	37
180	Inflammation in Right Ventricular Failure: Does It Matter?. 2018 , 9, 1056	19
179	Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. 2018 , 272S, 11-19	43
178	Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study. <i>Clinical Rheumatology</i> , 2018 , 37, 3373-3380	3.9 3

177	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). 2018 , 154, 862-871		47
176	Identifying early pulmonary arterial hypertension in patients with systemic sclerosis. 2018 , 51,		4
175	Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension.. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 30-38	2.3	2
174	The Right Heart International Network (RIGHT-NET): Rationale, Objectives, Methodology, and Clinical Implications. 2018 , 14, 443-465		12
173	Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists. 2018 , 14, 271-281		8
172	Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. 2018 , 14, 403-411		2
171	Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension. 2018 , 5, 864-875		15
170	Pulmonary arterial hypertension associated to systemic erythematosus: Molecular characterization of 3 cases. 2018 , 151, 111-115		
169	Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. 2018 , 27, 1742-1752		25
168	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018 , 37, 2989-2998	3.9	5
167	Nothing but a Number? Age and Precision Treatment in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 986-988	10.2	
166	Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. 2018 , 27, 1769-1777		11
165	ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients. 2018 , 273, 203-206		3
164	Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension. 2018 , 48, 839-853		4
163	Long-term survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Insights from a referral center in Portugal. 2018 , 37, 749-757		8
162	Risk stratification in pulmonary arterial hypertension. 2018 , 24, 407-415		8
161	Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease. <i>Clinical Rheumatology</i> , 2019 , 38, 3619-3626	3.9	2
160	Screening for pulmonary arterial hypertension in systemic sclerosis. 2019 , 28,		21

159	Early manifestation of myocardial involvement in systemic sclerosis. 2019 , 38, 299-303		
158	Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil. 2019 , 25, 100373		2
157	Metabolomics of exercise pulmonary hypertension are intermediate between controls and patients with pulmonary arterial hypertension. 2019 , 9, 2045894019882623		8
156	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). <i>Arthritis Research and Therapy</i> , 2019 , 21, 217	5.7	20
155	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. 2019 ,		1
154	A review of exercise pulmonary hypertension in systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 225-237	2.3	0
153	Early manifestation of myocardial involvement in systemic sclerosis. 2019 , 38, 299-303		3
152	Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. 2019 , 9, 2045894019862435		26
151	Analysis of Biphasic Right Ventricular Outflow Doppler Waveform in Patients with Pulmonary Hypertension. 2019 , 60, 108-114		1
150	Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry. 2019 , 211, 63-71.e6		9
149	Pulmonary Hypertension Associated with Connective Tissue Disease. 2019 , 40, 173-183		15
148	Pulmonary Complications of Systemic Lupus Erythematosus. 2019 , 40, 227-234		36
147	Pulmonary and Bronchiolar Involvement in Sjogren's Syndrome. 2019 , 40, 235-254		18
146	Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. 2019 , 71, 1691-1700		7
145	Common Causes of Pain in Systemic Sclerosis: Frequency, Severity, and Relationship to Disease Status, Depression, and Quality of Life. 2019 , 20, 331-336		3
144	The Clinical Utility and Enduring Versatility of Stress Echocardiography. <i>Heart Lung and Circulation</i> , 2019 , 28, 1376-1383	1.8	5
143	Capillary Proliferation in Systemic-Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. 2019 , 1, 26-36		4
142	Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis. 2019 , 53,		9

141	Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis. <i>Internal Medicine</i> , 2019 , 58, 593-601	1.1	1
140	Predictors of exercise-induced pulmonary hypertension in patients with connective tissue disease. 2019 , 34, 1509-1518		2
139	Personalisierte Medizin bei pulmonaler Hypertonie. 2019 , 16, 76-87		
138	Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 82	5.7	14
137	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). 2019 , 83, 842-945		67
136	Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. 2019 , 2019, 4569826		34
135	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. 2019 , 22, 921-928		10
134	30 Advances in medical and interventional treatments for CTEPH. 2019 ,		
133	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. 2019 , 25,		
132	27 Lower limb ischaemia in patients undergoing VA ECMO. 2019 ,		
131	28 Should we be using digoxin in 2018?. 2019 ,		
130	29 Management of pulmonary hypertension in systemic lupus erythematosus patients. 2019 ,		
129	Postural orthostatic tachycardia syndrome in primary care: diagnosis, treatment and a case of African-American man presenting with POTS. 2019 , 12,		1
128	Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models. 2019 , 35, 22		2
127	Early Detection of Pulmonary Hypertension in Connective Tissue Disease. 2019 , 26, 1		
126	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. 2019 , 10, 125-170		39
125	Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. 2019 , 19, 230		10
124	Systemic sclerosis. 2019 , 291-329		

123	Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. 2019 , 11, 323-333	8
122	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. 2019 , 71, 805-816	17
121	Pulmonary Hypertension. 2019 , 327-341.e9	
120	Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients. 2019 , 59, 1	16
119	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. 2019 , 53,	21
118	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. 2020 , 47, 89-98	7
117	Concurrent onset of acute lupus myocarditis, pulmonary arterial hypertension and digital gangrene in a lupus patient: a possible role of vasculitis to the rare disorders. 2020 , 4, 21-27	
116	Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. 2020 , 300, 228-235	8
115	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. 2020 , 79, 370-378	24
114	Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. 2020 , 50, 473-479	8
113	Acute Respiratory Failure in Interstitial Lung Disease Complicated by Pulmonary Hypertension. 2020 , 161, 105825	
112	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. 2020 , 11, 1623-1639	9
111	Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan. 2020 , 98, 653-658	0
110	Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. 2020 , 23, 1276-1287	1
109	Pulmonary arterial hypertension screening practices in scleroderma patients among Canadian rheumatologists.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 237-241	2.3 1
108	Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. 2020 , 10, 2045894020935291	3
107	Clinical Characteristics and Factors Associated with Disease Progression in Chinese Patients with Connective Tissue Disease and Pulmonary Arterial Hypertension. 2020 , 45, 475-479	
106	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. 2020 , 29, 1955-1960	3

105	Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension. 2020 , 9,	6
104	Compromiso pulmonar en síndrome de Sjögren. 2020 , 27, 109-124	
103	Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: A national cohort study in taiwan. 2020 , 50, 957-962	5
102	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. 2020 , 158, 350-358	6
101	Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA. 2020 , 6,	3
100	Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. 2020 , 39, 464-472	11
99	The lung in systemic lupus erythematosus. 2021 , 427-438	
98	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. 2021 , 73, 295-304	10
97	Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. 2021 , 159, 781-790	3
96	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). <i>Rheumatology</i> , 2021 , 60, 872-880	3.9 0
95	Asymptomatic necrotizing myositis in a young male with progressive interstitial lung disease. 2021 , 32, 101374	0
94	Pharmacological Management of Sjögren Syndrome. 2021 , 197-215	0
93	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. 2021 , 73, 837-847	9
92	Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study. 2021 , 11, 20458940211011329	3
91	Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases. 2021 , 14,	1
90	Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: A study from China. 2021 , 22, 925	2
89	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. 2021 , 2, 63-78	
88	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. 2021 , 40, 1251-1266	1

87	Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure. 2021 , 19, 202	2
86	Pulmonary hypertension phenotypes in patients with systemic sclerosis. 2021 , 30,	5
85	Successful treatment of pulmonary hypertension with immunosuppressive therapy in a case of anti-synthetase syndrome. 2021 , 48, e545-e546	1
84	The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension. 2021 , 9, 1458	0
83	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. 2021 , 59, 709-740	2
82	Pulmonary Hypertension Associated with Connective Tissue Disease. 2014 , 139-166	1
81	Lung Transplantation for Connective Tissue Disease-Associated Lung Disease. 2014 , 179-191	1
80	Pulmonary hypertension: biomarkers. 2013 , 218, 77-103	4
79	Pulmonary Hypertension: Biomarkers. 2013 , 77-103	6
78	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. 2013 , 23, 1211-20	7
77	Systemic Sclerosis. 2013 , 955-969	1
76	Clinical features of systemic sclerosis. 2011 , 1373-1385.e2	8
75	Pulmonary Hypertension. 2012 , 1696-1718	5
74	Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. 2020 , 25, 863-871	14
73	Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 292-301	10.2 32
72	Clinical features. 2011 , 81-99	1
71	The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. 2019 , 8,	3
70	Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis. 2013 , 8, e78001	13

- 69 Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. **2020**, 15, e0243651 1
- 68 Review of the diagnosis and pharmacological management of pulmonary arterial hypertension in connective tissue disease. **2016**, 16, 14-22 1
- 67 [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis]. **2015**, 87, 49-56 1
- 66 Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. **2018**, 16, 125-135 6
- 65 Primary Sjögren's Syndrome and Cardiovascular Disease. **2020**, 18, 447-454 11
- 64 Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. **2021**, 24, 1419-1426
- 63 Hypertension artérielle pulmonaire des connectivites. **2009**, 193, 1911-1919
- 62 Pulmonary Hypertension and Cor Pulmonale. **2011**, 353-371
- 61 Pulmonary Arterial Hypertension Related to Scleroderma and Collagen Vascular Diseases. **2011**, 1011-1022
- 60 A 28-Year-Old Woman with Early Diffuse Scleroderma and Shortness of Breath. **2011**, 115-125
- 59 Pulmonary management of systemic sclerosis. **2011**, 1413-1425.e1
- 58 Pulmonary Hypertension in Older Patients. **2012**, 111-131
- 57 Pulmonary Hypertension in Interstitial Lung Disease. **2012**, 121-135
- 56 Pulmonary Manifestations in Mixed Connective Tissue Disease. **2014**, 73-82
- 55 Cardiopulmonary Exercise Testing in Pulmonary Hypertension. **2015**, 265-301
- 54 Approach to the Patient with Elevated Pulmonary Arterial Pressure. **2015**, 165-201
- 53 Pulmonary management of systemic sclerosis. **2015**, 1200-1212
- 52 The heart in rheumatic disease. **2015**, 267-273

- 51 The importance of stress echocardiography. **2015**, 42, 599-610
- 50 Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community. **2016**, 63-79
- 49 Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators. **2016**, 307-325 1
- 48 Assessing Disease State in the Pulmonary Vasculature in Clinical Practice and Research. **2016**, 219-229
- 47 Clinical Assessment of Pulmonary Hypertension. **2017**, 403-409
- 46 Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy. **2017**, 691-700
- 45 Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population. **2017**, 16, 68-75
- 44 PH Professional Network: Screening for Caregiver's Burden in Management of Scleroderma: Pulmonary Arterial Hypertension. **2017**, 16, 85-87
- 43 [Risk stratification methods and their significance in pulmonary arterial hypertension]. **2019**, 91, 150-157
- 42 Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. **2021**, 23, 118 1
- 41 Beyond Scleroderma: Pulmonary Arterial Hypertension in Patients with Other Connective Tissue Diseases. **2020**, 51-60
- 40 Increase in Pulmonary Artery Pressures. **2021**, 101-109
- 39 Precision Medicine in Pulmonary Hypertension. **2020**, 241-255
- 38 Exercise Pulmonary Hypertension. **2020**, 1-27
- 37 Anti-inflammatory and immunosuppressive agents in PAH. **2013**, 218, 437-76 12
- 36 [The place of riociguat in the treatment of patients with pulmonary arterial hypertension associated with systemic connective tissue diseases]. *Kardiologiya*, **2020**, 60, 92-101 1.5
- 35 Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. **2010**, 1, 11-20
- 34 Successful Early Immunosuppressive Therapy for Pulmonary Arterial Hypertension due to Takayasu arteritis: Two Case Reports and a Review of Similar Case Reports in the English Literature. *Internal Medicine*, **2021**, 1.1

33	Pulmonary Hypertension Associated with Connective Tissue Disease. <i>Cardiology Clinics</i> , 2022 , 40, 29-43	2.5	1
32	Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. <i>Rheumatology</i> , 2021 ,	3.9	3
31	The role of TGF- β 1/BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 288	5.7	1
30	Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
29	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
28	Systemic sclerosis in Asians: Are there racial differences?. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 98-109	2.3	0
27	High prevalence of occult left ventricular diastolic dysfunction detected by exercise stress test in systemic sclerosis.. <i>Scientific Reports</i> , 2022 , 12, 2423	4.9	1
26	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.. <i>Scientific Reports</i> , 2022 , 12, 5289	4.9	0
25	Is it Still 'Idiopathic'?: Features of Autoimmunity in IPAH.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022 ,	10.2	
24	Phenotyping exercise limitation of patients with Interstitial Fibrosing Lung Disease: the importance of exercise hemodynamics.. <i>Pulmonology</i> , 2022 ,	3.7	
23	Tratamento da HAP com enfoque nas doenças reumáticas. <i>Revista Paulista De Reumatologia</i> , 2014 , 36-43	0.1	
22	Investigaçã diagnóstica da hipertensã pulmonar. <i>Revista Paulista De Reumatologia</i> , 2014 , 17-23	0.1	
21	Os novos tratamentos para HAP modificaram a mortalidade dos nossos pacientes?. <i>Revista Paulista De Reumatologia</i> , 2014 , 44-47	0.1	
20	A potential model of systemic sclerosis with pulmonary hypertension induced by monocrotaline plus bleomycin. <i>Clinical and Experimental Hypertension</i> , 1-7	2.2	
19	Exercise Rehabilitation Training in Patients with Pulmonary Hypertension: A Review. <i>Heart Lung and Circulation</i> , 2022 ,	1.8	0
18	Hemodynamic Responses to Provocative Maneuvers during Right Heart Catheterization. <i>Annals of the American Thoracic Society</i> ,	4.7	
17	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. <i>European Heart Journal Cardiovascular Imaging</i> ,	4.1	1
16	PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH A SYSTEMIC SCLEROSIS: REVIEW OF LITERATURE. 2015 , 32-39		1

- 15 Pulmonary Arterial Pressure Changes Under Dobutamine Stress Echocardiography in Non-Anemic Iron Deficient COPD Subjects. Volume 17, 1943-1949
- 14 Pulmonary Hypertension in Scleroderma Evaluation and Management. **2022**, 101468 ○
- 13 Association of maternal main pulmonary arterial diameter and neonatal birth weight: a study based on pulmonary arterial hypertension. ○
- 12 Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. 2
- 11 Cathepsin S Inhibition Suppresses Experimental Systemic Lupus Erythematosus-Associated Pulmonary Arterial Remodeling. **2022**, 23, 12316 ○
- 10 A case of glucocorticoid-resistant adult Still disease complicated by pulmonary hypertension and interstitial lung disease. ○
- 9 Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment. ○
- 8 Impact of Hormonal-Anabolic Deficiencies in Idiopathic Pulmonary Arterial Hypertension. **2023**, 19, 115-123 ○
- 7 Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis. **2023**, 19, 45-54 ○
- 6 Clinical characteristics and prognosis of connective tissue disease-associated pulmonary arterial hypertension. ○
- 5 A Case of Anti-synthetase Syndrome that Relapsed with Pulmonary Arterial Hypertension and Malignancy. **2023**, ○
- 4 In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study. ○
- 3 Systemic Lupus Erythematosus and Pulmonary Hypertension. **2023**, 24, 5085 ○
- 2 10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry. ○
- 1 Lung Disease in Systemic Lupus Erythematosus, Myositis, Sjögren Disease, and Mixed Connective Tissue Disease. **2023**, 223-239 ○